Clinical and Molecular Hepatology

Search

Close

Ahead-of print

Articles in E-pub version are posted online ahead of regular printed publication.

Reviews Stem cell exosomes: new hope and future potential for relieving liver fibrosis
Lihua Li, Yongjie Liu, Kunpeng Wang, Jinggang Mo, Zhiyong Weng, Hao Jiang, Chong Jin
DOI: 10.3350/cmh.2024.0854  [Epub ahead of print]
Editorials Stabilizing Hepatic Fatty Acid Oxidation: USP29 Secures Acyl-CoA Synthesis through ACSL5
Myeung Gi Choi, Na Young Lee, Ja Hyun Koo
DOI: 10.3350/cmh.2024.0971  [Epub ahead of print]
Replys to Correspondence Reply to correspondence on “Understanding the impact on digestive disease in the post-COVID-19 condition”
Yang-Hyun Baek
DOI: 10.3350/cmh.2024.0966  [Epub ahead of print]
Letters to the Editor Insights on Risk Score Development: Considerations for Early-Stage Hepatocellular Carcinoma Models
Zhanna Zhang, Gongqiang Wu
DOI: 10.3350/cmh.2024.0958  [Epub ahead of print]
Correspondences Reply to “Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
DOI: 10.3350/cmh.2024.0946  [Epub ahead of print]
Editorials A novel clinical trial for primary sclerosing cholangitis from Asia: all regional endeavors should improve global management of PSC
Atsumasa Komori
DOI: 10.3350/cmh.2024.0945  [Epub ahead of print]
Correspondences Correspondence on Letter Regarding “Contemporary Awareness of Viral Hepatitis between 2012 and 2022 among Korean Adults”
Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
DOI: 10.3350/cmh.2024.0944  [Epub ahead of print]
Correspondence on Letter regarding “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
Moon Haeng Hur, Yoon Jun Kim
DOI: 10.3350/cmh.2024.0943  [Epub ahead of print]
Editorials Challenges and Innovations in PSC Clinical Trials: Evaluating HK-660S and the Path Forward
Nilanga Nishad
DOI: 10.3350/cmh.2024.0942  [Epub ahead of print]
Correspondences Response to the letter
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
DOI: 10.3350/cmh.2024.0937  [Epub ahead of print]
Reviews ALCOHOL-ASSOCIATED LIVER DISEASE: NATURAL HISTORY, MANAGEMENT AND NOVEL TARGETED THERAPIES
Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós, Ana Clemente-Sánchez, Hugo Hugo López-Pelayo, Ramón Bataller
DOI: 10.3350/cmh.2024.0709  [Epub ahead of print]
Correspondences Correspondence on editorial regarding “Understanding the impact on digestive disease in the post-COVID-19 condition”
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
DOI: 10.3350/cmh.2024.0935  [Epub ahead of print]
Editorials Stroma-tology: Predicting Recurrence in Cholangiocarcinoma
Sergi Marco, Chiara Braconi
DOI: 10.3350/cmh.2024.0932  [Epub ahead of print]
Momentum Towards Simplifying and Expanding Treatment for Chronic Hepatitis B: The Body of Evidence Continues to Grow
Robert J. Wong
DOI: 10.3350/cmh.2024.0929  [Epub ahead of print]
Letters to the Editor Prevalence of steatotic liver disease and associated fibrosis in the general population: an epidemiological survey
Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
DOI: 10.3350/cmh.2024.0921  [Epub ahead of print]
Urgent Need for Education on Hepatocellular Carcinoma Surveillance Among High-Risk Population in China
Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang
DOI: 10.3350/cmh.2024.0813  [Epub ahead of print]
Reviews Long-term Outcomes and Risk Modifiers of MASLD Between Lean and Non-Lean Populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
DOI: 10.3350/cmh.2024.0631  [Epub ahead of print]
Correspondences Correspondence on letter to the editor regarding “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
DOI: 10.3350/cmh.2024.0916  [Epub ahead of print]
Reviews Bioactive metabolites: a clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun
DOI: 10.3350/cmh.2024.0782  [Epub ahead of print]
Correspondences Correspondence on Editorial regarding “Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer
DOI: 10.3350/cmh.2024.0781  [Epub ahead of print]
Letters to the Editor Chronic hepatitis B, Extrahepatic Malignancies and the Use of Antiviral Drugs
Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
DOI: 10.3350/cmh.2024.0906  [Epub ahead of print]
Snapshots MODULATION OF LYMPHATIC VESSELS IN MANAGEMENT OF LIVER DISEASE AND COMPLICATIONS
Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur
DOI: 10.3350/cmh.2024.0793  [Epub ahead of print]
Original Articles Antiviral Therapy for Chronic Hepatitis B with Mildly Elevated Aminotransferase: A Rollover Study from the TORCH-B Trial
Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin
DOI: 10.3350/cmh.2024.0640  [Epub ahead of print]
Correspondences Correspondence on Editorial regarding “Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease”
Young Eun Chon, Jung Hwan Yu, Seung Up Kim
DOI: 10.3350/cmh.2024.0878  [Epub ahead of print]
Reply to: “Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers”
Satya Priya Sharma, Ki Tae Suk
DOI: 10.3350/cmh.2024.0872  [Epub ahead of print]
Original Articles Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
Yang Liu, Fan Peng, Siyuan Wang, Huanmin Jiao, Kaixiang Zhou, Wenjie Guo, Shanshan Guo, Miao Dang, Huanqin Zhang, Weizheng Zhou, Xu Guo, Jinliang Xing
DOI: 10.3350/cmh.2024.0527  [Epub ahead of print]
Letters to the Editor Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
Wei Feng, Qile Wang, Qingwang Ye
DOI: 10.3350/cmh.2024.0887  [Epub ahead of print]
Replys to Correspondence Reply: Correspondence: “Transcriptomic signature in hepatocellular carcinoma to predict immunotherapy response.”
Hiroaki Kanzaki, Yujin Hoshida
DOI: 10.3350/cmh.2024.0886  [Epub ahead of print]
Reply to: Correspondence on Editorial regarding “Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Antonio Bertoletti, Anthony T Tan
DOI: 10.3350/cmh.2024.0867  [Epub ahead of print]
Editorials Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease
Won Sohn
DOI: 10.3350/cmh.2024.0823  [Epub ahead of print]
Letters to the Editor Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
Xiping Shen, Ji Wu
DOI: 10.3350/cmh.2024.0794  [Epub ahead of print]
Original Articles Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian
DOI: 10.3350/cmh.2024.0359  [Epub ahead of print]
Letters to the Editor Contemporary Awareness of Viral Hepatitis between 2012 and 2022 among Korean Adults
Donghee Kim, Won Kim, Aijaz Ahmed
DOI: 10.3350/cmh.2024.0849  [Epub ahead of print]
Editorials Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details
Kyung-Ah Kim
DOI: 10.3350/cmh.2024.0827  [Epub ahead of print]
Understanding the impact on digestive disease in the post-COVID-19 condition
Yang-Hyun Baek
DOI: 10.3350/cmh.2024.0856  [Epub ahead of print]
The Urgent Need for Multidisciplinary Approaches in Managing Alcohol-Associated Liver Disease
Soon Sun Kim, Jae Youn Cheong
DOI: 10.3350/cmh.2024.0847  [Epub ahead of print]
Correspondences Correspondence on the Editorial regarding “The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients”
Young-Joo Jin, Seung Up Kim
DOI: 10.3350/cmh.2024.0846  [Epub ahead of print]
Letters to the Editor Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
DOI: 10.3350/cmh.2024.0832  [Epub ahead of print]
Correspondences Correspondence on Letter regarding “Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors”
Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
DOI: 10.3350/cmh.2024.0830  [Epub ahead of print]
Correspondence on Letter regarding “Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response.”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
DOI: 10.3350/cmh.2024.0829  [Epub ahead of print]
Original Articles Self-testing strategy to eliminate Hepatitis C as per WHO’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
DOI: 10.3350/cmh.2024.0484  [Epub ahead of print]
Correspondences Correspondence on Letter regarding “Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma.”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee
DOI: 10.3350/cmh.2024.0828  [Epub ahead of print]
Review Articles Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho
DOI: 10.3350/cmh.2024.0734  [Epub ahead of print]
Original Articles USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li
DOI: 10.3350/cmh.2024.0478  [Epub ahead of print]
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi
DOI: 10.3350/cmh.2024.0451  [Epub ahead of print]
Reviews Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
DOI: 10.3350/cmh.2024.0441  [Epub ahead of print]
Letters to the Editor Accountability in AI Medicine: A Critical Appraisal of ChatGPT in Patient Self-Management and Screening
Jiawen Wang, Tian Xia
DOI: 10.3350/cmh.2024.0769  [Epub ahead of print]
Correspondences Reply to Letter regarding “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
Yuri Cho, Dae Won Jun
DOI: 10.3350/cmh.2024.0818  [Epub ahead of print]
Editorials The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients
Mirko Zoncapè, Emmanuel A. Tsochatzis
DOI: 10.3350/cmh.2024.0817  [Epub ahead of print]
Correspondences Correspondence on Editorial regarding “Towards unification of liver stiffness measurement cutoffs”
Jung Hwan Yu, Seung Up Kim
DOI: 10.3350/cmh.2024.0815  [Epub ahead of print]
Original Articles Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park
DOI: 10.3350/cmh.2024.0629  [Epub ahead of print]
Editorials HCC surveillance after sustained virological response in chronic hepatitis C
Ho Soo Chun, Minjong Lee
DOI: 10.3350/cmh.2024.0795  [Epub ahead of print]
Towards unification of liver stiffness measurement cutoffs
Yangyue Zhang, Vincent Wai-Sun Wong
DOI: 10.3350/cmh.2024.0766  [Epub ahead of print]
Letters to the Editor Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
DOI: 10.3350/cmh.2024.0719  [Epub ahead of print]
Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma
Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
DOI: 10.3350/cmh.2024.0628  [Epub ahead of print]
Letter regarding “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
Xiao-Song Li, Xi-Ping Shen, Hang Li
DOI: 10.3350/cmh.2024.0784  [Epub ahead of print]
Correspondences Correspondence on Editorial regarding “Spotting Undiagnosed Significant Liver Fibrosis in the General Population: Impact on Subsequent Clinical Care”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
DOI: 10.3350/cmh.2024.0777  [Epub ahead of print]
Correspondence on Letter regarding “A complement to epigenetics in MASLD”
Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
DOI: 10.3350/cmh.2024.0761  [Epub ahead of print]
Correspondence on Editorial regarding “KCTD17 as a RAS stabilizer in hepatocellular carcinoma progression”
Sang Bae Lee, KyeongJin Kim
DOI: 10.3350/cmh.2024.0750  [Epub ahead of print]
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD
Baokai Sun, Likun Zhuang
DOI: 10.3350/cmh.2024.0744  [Epub ahead of print]
Editorials Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors
Naoshi Nishida
DOI: 10.3350/cmh.2024.0739  [Epub ahead of print]
Spotting Undiagnosed Significant Liver Fibrosis in the General Population: Impact on Subsequent Clinical Care
Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip
DOI: 10.3350/cmh.2024.0737  [Epub ahead of print]
Letters to the Editor Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma
Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
DOI: 10.3350/cmh.2024.0682  [Epub ahead of print]
Editorials Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response
Hiroaki Kanzaki, Yujin Hoshida
DOI: 10.3350/cmh.2024.0726  [Epub ahead of print]
Correspondences Reply to: “From invasive to intuitive: the emerging role of non-invasive models in hepatic decompensation”
Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi
DOI: 10.3350/cmh.2024.0723  [Epub ahead of print]
Editorials Identification of KCTD17 as a RAS stabilizer in hepatocellular carcinoma
Rainbow Wing Hei LEUNG, Terence Kin Wah LEE
DOI: 10.3350/cmh.2024.0718  [Epub ahead of print]
Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers
Soon Kyu Lee, Jong Young Choi
DOI: 10.3350/cmh.2024.0716  [Epub ahead of print]
A complement to epigenetics in MASLD
Johanna K. DiStefano, Glenn S. Gerhard
DOI: 10.3350/cmh.2024.0704  [Epub ahead of print]
TM6SF2 and PNPLA3: a potential dynamic duo?
Andrea Caddeo, Rosellina M. Mancina
DOI: 10.3350/cmh.2024.0703  [Epub ahead of print]
From Invasive to Intuitive: The Emerging Role of Non-Invasive Models in Hepatic Decompensation
Akhil Deshmukh, Rakhi Maiwall
DOI: 10.3350/cmh.2024.0661  [Epub ahead of print]
Correspondences Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?
Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
DOI: 10.3350/cmh.2024.0638  [Epub ahead of print]
Review Articles Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
DOI: 10.3350/cmh.2024.0431  [Epub ahead of print]
Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation
Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia
DOI: 10.3350/cmh.2024.0323  [Epub ahead of print]
Editorials MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors
Rex Wan-Hin Hui, Lung-Yi Mak
DOI: 10.3350/cmh.2024.0630  [Epub ahead of print]
Letters to the Editor Presence of liver fibrosis in chronic hepatitis B patients with varying serum HBV DNA levels
Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang
DOI: 10.3350/cmh.2024.0602  [Epub ahead of print]
Replys to Correspondence Reply to correspondence regarding “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma
Martina Mang Leng LEI, Terence Kin Wah LEE
DOI: 10.3350/cmh.2024.0621  [Epub ahead of print]
Correspondences Correspondence to letter to the editor on "Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B"
Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
DOI: 10.3350/cmh.2024.0619  [Epub ahead of print]
Editorials From Past to Pandemic: Health Disparities in U.S. Hepatobiliary Cancer Mortality Before and During COVID-19
Ilona Argirion
DOI: 10.3350/cmh.2024.0597  [Epub ahead of print]
Reviews Precision medicine and nucleotide-based therapeutics to treat MASH
Andrea Caddeo, Stefano Romeo
DOI: 10.3350/cmh.2024.0438  [Epub ahead of print]
Snapshots MASLD across women’ reproductive lifespan and issues
Clara Meda, Arianna Dolce, Sara Della Torre
DOI: 10.3350/cmh.2024.0419  [Epub ahead of print]
Correspondences Correspondence on Editorial regarding “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian
DOI: 10.3350/cmh.2024.0590  [Epub ahead of print]
Editorials UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma
Martina Mang Leng LEI, Terence Kin Wah LEE
DOI: 10.3350/cmh.2024.0568  [Epub ahead of print]
Original Articles Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Liu Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi
DOI: 10.3350/cmh.2024.0198  [Epub ahead of print]
Reviews Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
DOI: 10.3350/cmh.2024.0246  [Epub ahead of print]

Go to Top